P.A.M. Transport Services (NASDAQ:PTSI) had a decrease of 1.54% in short interest. PTSI’s SI was 44,800 shares in March as released by FINRA. Its down 1.54% from 45,500 shares previously. With 6,700 avg volume, 7 days are for P.A.M. Transport Services (NASDAQ:PTSI)’s short sellers to cover PTSI’s short positions. The stock decreased 2.27% or $0.37 on March 24, reaching $15.9. About 7,194 shares traded. P.A.M. Transportation Services, Inc. (NASDAQ:PTSI) has declined 12.34% since August 17, 2016 and is downtrending. It has underperformed by 19.84% the S&P500.
director Lewis Cantley of Agios Pharmaceuticals Inc, sold some 2,036 of the stock exchange listed company shares valued at $108,132 U.S Dollars with an average of $53.1 stock price for a share. This trade decreased his ownership of the Company to 0.55% market cap or 238,560 shares. The provided info is according to a SEC filing dated 24-03-2017.
Analysts await Agios Pharmaceuticals Inc (NASDAQ:AGIO) to report earnings on May, 4. They expect $-1.83 EPS, down 200.00% or $1.22 from last year’s $-0.61 per share. After $-1.34 actual EPS reported by Agios Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 36.57% negative EPS growth.
Since September 27, 2016, it had 0 insider buys, and 11 insider sales for $24.50 million activity. Biller Scott sold $354,090 worth of stock. On Monday, February 27 the insider NELSEN ROBERT sold $12.00M. 2,504 shares were sold by Cantley Lewis Clayton Jr., worth $122,546. The insider Schenkein David P sold $151,410.
Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $2.33 billion. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. It currently has negative earnings. The Company’s cancer product candidates are enasidenib and ivosidenib , which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Investors sentiment decreased to 1.1 in 2016 Q4. Its down 0.62, from 1.72 in 2016Q3. It dropped, as 23 investors sold Agios Pharmaceuticals Inc shares while 45 reduced holdings. 19 funds opened positions while 56 raised stakes. 37.23 million shares or 3.48% more from 35.97 million shares in 2016Q3 were reported. 2.80 million were accumulated by Capital Interest Investors. Blackrock Institutional Trust Na invested 0.01% in Agios Pharmaceuticals Inc (NASDAQ:AGIO). Utah Retirement Systems accumulated 5,600 shares or 0.01% of the stock. Price T Rowe Associate Md reported 0.01% in Agios Pharmaceuticals Inc (NASDAQ:AGIO). Guardian Tru has 816,200 shares for 0.27% of their portfolio. Metropolitan Life Communications stated it has 0% in Agios Pharmaceuticals Inc (NASDAQ:AGIO). Nationwide Fund Advsr owns 9,604 shares or 0% of their US portfolio. Td Asset Mngmt reported 0% stake. Pacad Investment reported 2,200 shares. Brown Advisory invested 0.02% in Agios Pharmaceuticals Inc (NASDAQ:AGIO). Jennison Assocs Limited Liability Corporation has 169,799 shares for 0.01% of their portfolio. Envestnet Asset Mgmt holds 21 shares or 0% of its portfolio. California Pub Employees Retirement Systems accumulated 0% or 35,600 shares. Axa invested 0.01% of its portfolio in Agios Pharmaceuticals Inc (NASDAQ:AGIO). Cap Ww reported 663,000 shares or 0.01% of all its holdings.
Among 13 analysts covering Agios Pharmaceuticals (NASDAQ:AGIO), 8 have Buy rating, 0 Sell and 5 Hold. Therefore 62% are positive. Agios Pharmaceuticals has $132 highest and $47 lowest target. $71.73’s average target is 29.78% above currents $55.27 stock price. Agios Pharmaceuticals had 22 analyst reports since July 23, 2015 according to SRatingsIntel. On Thursday, January 21 the stock rating was initiated by Credit Suisse with “Outperform”. JP Morgan upgraded Agios Pharmaceuticals Inc (NASDAQ:AGIO) rating on Monday, June 13. JP Morgan has “Overweight” rating and $62 target. Canaccord Genuity maintained Agios Pharmaceuticals Inc (NASDAQ:AGIO) rating on Friday, August 7. Canaccord Genuity has “Hold” rating and $93 target. The firm has “Buy” rating by Needham given on Monday, October 24. The stock of Agios Pharmaceuticals Inc (NASDAQ:AGIO) earned “Hold” rating by Roth Capital on Wednesday, August 5. The company was initiated on Friday, August 19 by BTIG Research. The stock of Agios Pharmaceuticals Inc (NASDAQ:AGIO) earned “Buy” rating by SunTrust on Wednesday, March 30. The firm has “Buy” rating by Canaccord Genuity given on Monday, June 13. The stock has “Neutral” rating by Roth Capital on Monday, November 9. On Wednesday, March 2 the stock rating was initiated by Janney Capital with “Neutral”.
The stock increased 2.11% or $1.14 during the last trading session, reaching $55.27. About 360,423 shares traded. Agios Pharmaceuticals Inc (NASDAQ:AGIO) has risen 35.63% since August 17, 2016 and is uptrending. It has outperformed by 28.13% the S&P500.
